Kite Presents Results of Yescarta (axicabtagene ciloleucel) in P-II ZUMA-5 Trial for R/R Follicular Lymphoma at EHA 2021

 Kite Presents Results of Yescarta (axicabtagene ciloleucel) in P-II ZUMA-5 Trial for R/R Follicular Lymphoma at EHA 2021

Kite Presents Results of Yescarta (axicabtagene ciloleucel) in P-II ZUMA-5 Trial for R/R Follicular Lymphoma at EHA 2021

Shots:

  • The P-II ZUMA-5 trial assessing Yescarta in 146 patients aged ≥18rs. with r/r iNHL include FL, prior treated with at least 2L of systemic therapy
  • Results: 94% of patients achieved a response @18mos., & 2EPs of mPFS and OS were not yet reached. In a weighted analysis, the results compared with ZUMA-5 patients vs SCHOLAR-5 patients, therapy showed superior OS & PFS over currently available treatments
  • Patients achieved a response (94% vs 50%) @median follow-up of 26.2 mos., reduction in risk of disease progression (58% vs 70%), relapse or death vs current therapies in a control cohort, m-PFS & OS (12.7 & 59.8 mos.) in a control cohort, respectively

Click here to­ read full press release/ article | Ref: Business Wire | Image: Business Wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post